ZHONG JI LS (00767) announced that on August 4, 2025, the company (buyer) entered into a non-legally binding memorandum of understanding with China International Bone and Joint Medical Group Limited (seller). Under this agreement, the buyer intends to acquire (either directly or through its wholly-owned subsidiaries) while the seller intends to sell 100% of the total equity of Asian Comprehensive Cell Bank Limited (target company).
Based on information provided by the seller, the target company is primarily engaged in research and development of cell therapy, cellular drugs, and health longevity management services. The target company currently operates the Asian Comprehensive Cell Bank.
The Asian Comprehensive Cell Bank is the world's largest international autologous immune cell bank and the world's leading comprehensive international clinical cell bank that uniquely meets FDA, AABB, PIC/S cGMP, Isber-IRL, FACT, CAP, and ISBT 128 standards for both immune cells and stem cells. It addresses the global challenge of insufficient quantities of international standard cells and their safe and effective application, serving as the world's leading international cell transformation and application platform and a global leader in cell management.
The Asian Comprehensive Cell Bank is the only FDA-registered and recognized comprehensive international clinical cell bank in Asia for both immune cells and stem cells, and the only ISBER-IRL certified immune cell bank in Asia. This certification demonstrates that the Asian Comprehensive Cell Bank's entire process from cell collection, screening, testing, packaging, processing, storage, labeling to transportation meets FDA-recognized international standards, with cell management at a globally leading level.
Located in Hong Kong, the Asian Comprehensive Cell Bank can store and legally apply cells. Its testing and storage processes and reports are completed by Category I or Category II medical laboratory technologists recognized by the Hong Kong Department of Health, independently verified by Category I medical laboratory technologists, and subject to a dual verification process by laboratory directors, ensuring the entire process fully meets or exceeds local regulatory requirements and safety standards.
The Asian Comprehensive Cell Bank began operations on November 17, 2018, and possesses patented technologies in cancer prevention screening, NK cells, stem cells, and cartilage cells, along with 22 advanced medical testing platforms. Based on information provided by the seller, it can provide world-leading immune cell storage, cancer prevention screening, longevity medicine testing, health longevity management services, and research and development of cell therapy and cellular drugs in the fields of cancer prevention, anti-aging, and knee joint health for 300,000 people globally, with potential future revenue exceeding HK$30 billion.